50,103 Shares in Gilead Sciences, Inc. $GILD Acquired by Vise Technologies Inc.

Vise Technologies Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,103 shares of the biopharmaceutical company’s stock, valued at approximately $5,555,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences in the 4th quarter worth about $215,000. Alps Advisors Inc. increased its position in shares of Gilead Sciences by 1.1% during the first quarter. Alps Advisors Inc. now owns 17,596 shares of the biopharmaceutical company’s stock worth $1,972,000 after acquiring an additional 190 shares during the period. Cerity Partners LLC raised its stake in shares of Gilead Sciences by 47.8% during the first quarter. Cerity Partners LLC now owns 254,020 shares of the biopharmaceutical company’s stock valued at $28,463,000 after acquiring an additional 82,179 shares in the last quarter. Finally, Ballentine Partners LLC boosted its holdings in shares of Gilead Sciences by 7.0% in the first quarter. Ballentine Partners LLC now owns 23,371 shares of the biopharmaceutical company’s stock valued at $2,619,000 after purchasing an additional 1,535 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. BMO Capital Markets raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Argus raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $127.82.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 71,500 shares of company stock worth $8,336,040. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 3.7%

Gilead Sciences stock opened at $118.84 on Monday. The stock has a 50-day moving average price of $116.49 and a 200 day moving average price of $112.26. The company has a market capitalization of $147.46 billion, a price-to-earnings ratio of 23.67, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the company earned $2.02 earnings per share. The firm’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.